Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Feb
26
2021
New Jersey Adult-Use Recreational Cannabis Laws Provide Business Opportunities Sills Cummis & Gross P.C.
Jun
7
2014
Dietary Supplement Health and Education Act (DSHEA) – 20 Years Later – The Good, The Bad And The Ugly Sills Cummis & Gross P.C.
Jul
9
2019
Merck Sharp & Dohme Corp. v. Albrecht: The U.S. Supreme Court Weighs In On Preemption Sills Cummis & Gross P.C.
Jun
3
2012
Five Traps for the Unwary Licensee Sills Cummis & Gross P.C.
Nov
30
2018
In re Accutane Litigation: A Victory for Pharmaceutical Companies on Choice of Law and Label Warnings Sills Cummis & Gross P.C.
Aug
8
2014
Medical Devices: Parallel Claims Against Device Manufacturers post-Riegel? Sills Cummis & Gross P.C.
Jul
25
2019
Weeding through the NJ Medical Marijuana Law Amendments: What You Need to Know Sills Cummis & Gross P.C.
May
2
2020
Re-Imagining the Shopping Center Post-COVID: Zoning Changes Needed to Accommodate Store Features No Longer Deemed Convenience Amenities Sills Cummis & Gross P.C.
Mar
4
2020
Federal Preemption in the Wake of Albrecht: The U.S. Supreme Court Unexpectedly Levels the Playing Field Sills Cummis & Gross P.C.
Feb
25
2021
New Jersey Cannabis Legalization Imposes New Burdens on Employers Sills Cummis & Gross P.C.
Feb
4
2020
Will the Coronavirus Make Your Business Sick? Much Shelist, P.C.
Apr
20
2020
DEA Provides Three Exceptions to Key Regulations Addressing the Treatment of Controlled Substances at Hospitals and Clinics Much Shelist, P.C.
Aug
22
2013
Coming Clean: EPA Finally Adopts Industrial Wipes Standard Much Shelist, P.C.
Apr
20
2020
Pharmacists Authorized to Order and Administer COVID-19 Testing Much Shelist, P.C.
Mar
6
2018
Drug Testing an Employee Who Reports a Work-Related Accident? Special Rules Apply Much Shelist, P.C.
Apr
29
2020
Pharmacy Groups Request COVID-19 Testing Authority for California Pharmacists Much Shelist, P.C.
Dec
6
2017
DEA Relaxes Requirements for Use of Automated Dispensing Systems in Long-Term Care Facilities — Is Illinois Next? Much Shelist, P.C.
Mar
5
2019
2018 Farm Bill Legalizes Hemp, but Obstacles to Sale of CBD Products Remain Much Shelist, P.C.
Sep
16
2015
New Business Opportunities for Pharmacies: Do You Have the Required Licenses? Much Shelist, P.C.
Oct
8
2015
Medical Cannabis in Illinois: What Health Care Providers and Organizations Need to Know Much Shelist, P.C.
Oct
22
2015
Medical Cannabis in Illinois: What Employers Need to Know Much Shelist, P.C.
May
8
2021
FDA Proposes Risk-Based and Remote Inspection Strategies in New Report Sheppard, Mullin, Richter & Hampton LLP
Aug
25
2022
Healthcare Reforms Under the IRA: Expanding Access to Care Sheppard, Mullin, Richter & Hampton LLP
Jul
12
2019
Regulating E-Cigarettes Remains “Top Priority” For FDA Sheppard, Mullin, Richter & Hampton LLP
Oct
12
2015
Next Rx: New Medicare Part D Initiative Advances Role of Medication Management in Reform Sheppard, Mullin, Richter & Hampton LLP
Mar
20
2023
FDA Draft Guidance Signifies Acceptance of the Term “Milk” to Describe Plant-Based Alternatives Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2019
340B Program-Participating Hospitals Object to CMS’s Proposed Cuts to 340B Program Reimbursement: CMS’s Recent Information Collection Request Sheppard, Mullin, Richter & Hampton LLP
Jan
21
2024
FDA Issues Final Rule and Guidance on Direct-To-Consumer Prescription Drug Advertisements Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins